Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Keywords: 4-aminoquinolines; AMQ-protein complexes; Antimalarials design; Artemisinins; Bis(quinolyl)-piperazines; CQ-resistant malaria; Daraprim; Erythrocyte Membrane Proteins; Hydroxynaphthoquinones; Medicines for Malaria Venture; P. malariae; P. ovale; P. vivax; Paludrine; Plasmodium falciparum; Pyrimidine biosynthetic enzymes; Quinolines; SN10275; Synthetic Peroxides; agranulocytosis; antimalarial antifolates; antimalarial resistance; antimalarial targets; artemether-lumefantrine; artemisinins; arylaminoalcohols quinine; atovaquone; chemotherapy; chloroquine; dihydroartemisinin; haemozoin; halofantrine; intraerythrocytic parasite; iron II ferriprotoporphyrin IX; lumefantrine; malaria chemotherapy; malarial vaccine; mefloquine; membrane-associated FPIX; p-hydroxyanilino aromatic ring; piperaquine; proguanil; prophylaxis; protozoal parasite; pyrimethamine; pyronaridine-artesunate combination; shikimate pathway; sulfadoxine/ pyrimethamine (Fansidar); useful therapeutic life
Document Type: Research Article
Publication date: 01 December 2010
- Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing both original research papers and reviews describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.
Current Drug Discovery Technologies is an essential journal for all scientists and research managers involved in drug discovery who wish to keep abreast of all the modern techniques and technologies used in drug discovery. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content